Billiam James

Modern Myths: A trip back to the founding of the Church of Psycho-pharmacology, an illustration for a story by Dr. David Healy.

In 1957, interested in the fuss surrounding the new tranquilizers, she [Crusoe] dropped in to a World Congress of Psychiatry Meeting being held that year in Zurich. There was an extraordinary buzz — the excitement surrounding the discovery of chlorpromazine was growing not fading. It really did seem like a cure for schizophrenia or the harbinger of a cure that would arrive any day now.

The meeting was full of chatter about the next wonder drug about to appear and what it all meant…

…

It was openly accepted that the new College had been created by Sandoz, who had convened the Supper in Zurich. One delegate even joked that Sandoz’s boss, Rothlin, the President of the College, was the head of a new religion – a Pope. Rothlin though was a businessman – well maybe that’s what Pope’s were. Not someone anyone thought was likely to have had LSD himself.

Sandoz and other companies bankrolled the meeting, paid for the delegates to be there, paid for the delegates to be there, and put on the coaches that took them from Rome to Castel Gandolfo.”

Read Dr. David Healy’s full story: “Castel Gandolfo“.

Drug companies maximize the sales of new drugs by hyping their benefits while downplaying significant risks. In 2010 the European Medicines Agency began releasing patient-level data from the clinical trials used to approve new medicines in Europe – a development hailed by American, and European researchers and researchers around the world as a major step towards drug safety.

This process has been shut down by a lawsuit taken by two American corporations – AbbVie, makers of Humira, the number one selling medication in the world with projected sales of $10 billion in 2013; and InterMune, whose pulmonary-fibrosis drug Esbriet has recently been approved in Europe at a cost of over $40,000 per year.

Sign the petition here: Let us see Drug Data! Drug hazards are not “trade secrets”!

Read Dr. David Healy’s post here: Letter to Stacy London

Translations:
The posters are being translated into many languages including French, Dutch, Hindi, Kannada, Spanish, Mandarin, Italian, and German as part of RxISK‘s world-wide campaign for open data on pharmaceutical research and drug safety trials.

“There are many of us with bad Rheumatoid Arthritis or Crohn’s Disease who would gladly take these risks, especially if the drug produced a real benefit. We might be much less inclined to do for milder conditions. But in all cases the trade-off should be ours.

Ideally we should be helped by our doctors and pharmacists, but doctors and pharmacists who truly know what the problems can be. When AbbVie hide their clinical trial data, they make anyone who was involved in a clinical trial of their drug or a doctor prescribing it or pharmacist dispensing it into a potential accomplice to injury and perhaps homicide because the missing data is used to argue that ‘we’ve done trials and look there is no risk’.”

See full post: Lets do the AbbVie again by Dr. David Healy